Introduction {#Sec1}
============

The bacterial cell cycle is divided into three periods: after cell division and before initiation of chromosome replication (B or G1); chromosome replication (C or S); and cell division (D or G2)^[@CR1]^. Since chromosome replication and cell division (C and D periods) remain constant over a wide range of growth rates^[@CR2],[@CR3]^, the step committing cells to initiate chromosome replication largely determines bacterial proliferation rates. Bacteria like *Escherichia coli* or *Bacillus subtilis* can increase their growth rate by bypassing the B period and by initiating replication multiple times per division cycle^[@CR2]^. In contrast, *Caulobacter crescentus* strictly separates its cell cycle stages. An asymmetric division generates a sessile stalked (ST) cell, which directly reenters S-phase, and a motile swarmer (SW) cell that remains in G1 for a variable time depending on nutrient availability^[@CR4],[@CR5]^. Coincident with G1/S transition, motile SW cells undergo morphogenesis to gain sessility (Fig. [1a](#Fig1){ref-type="fig"}). But what determines the length of G1 in this organism has remained unclear.Fig. 1C-di-GMP controls the ShkA-TacA phosphorelay *in C. crescentus*.**a** Schematic of the *C. crescentus* cell cycle with swarmer and stalked cells colored in blue and orange, respectively, and the G1- and S-phases of the cell cycle indicated in similar colors. Stage-specific kinase (Kin) and phosphatase (Pho) activities of CckA are indicated with the coloring referring to stage-related activities. DivK and PleD that control the CckA switch are highlighted. **b** Schematic of the ShkA-ShpA-TacA phosphorelay. **c** Quantification of cells with stalks and SpmX-mCherry foci of strains expressing a chromosomal *spmX-mCherry* fusion and plasmid-driven *tacA*, *tacA*^*D54E*^, or *dgcZ*. EV, empty vector. The number of cells analyzed (*N*) is indicated above the graph. Also see Supplementary Fig. [1](#MOESM1){ref-type="media"}. **d** *spmX* promoter activity (plasmid pRKlac290-*spmX*) in indicated strains. IPTG indicates induction of *dgcZ* expression. Shown are mean values and standard deviations (*N* ≥ 2). **e** Phos-tag PAGE immunoblots of strains producing 3xFLAG-tagged ShkA or TacA from the native loci and expressing plasmid-borne PleD\*. Relative phosphorylation (rel. phos.) of TacA and ShkA were determined by calculating the ratio of intensities of phosphorylated and unphosphorylated bands normalized to this value of the wild type with empty vector control. **f** Phos-tag PAGE immunoblots of strains encoding 3xFLAG-tagged ShkA or TacA at the native loci or the respective mutant alleles encoding degradation-resistant variants TacA^DD^ or ShkA^DD^. Strains carried a plasmid for cumate-inducible expression of wild type or a catalytic mutant (AAL) of the phosphodiesterase (PDE) PA5295. Samples were harvested after addition cumate as indicated. PA5295^AAL^ samples were harvested 4 h post induction. Relative phosphorylation (rel. phos.) was normalized to the PA5295^AAL^ control. **g** In vitro phosphorylation of purified ShkA with different nucleotides present (1 mM, 100 μM, 10 μM). Positive (+) and negative (−) controls contained 100 μM c-di-GMP and ddH~2~O, respectively. Reactions were initiated by addition of 500 μM radiolabeled ATP and allowed to proceed for 15 min at room temperature. **h** In vitro phosphorylation assays with purified components (4 μM) of the ShkA-ShpA-TacA phosphorelay with (+) or without (−) c-di-GMP (76 μM). Reactions were initiated as described for **g**. Source data are provided as a Source Data file.

In *C. crescentus*, replication initiation is regulated by the cell cycle kinase CckA. CckA is a bifunctional enzyme that acts as a kinase for the replication initiation inhibitor CtrA in G1, but switches to being a phosphatase in S phase, resulting in the inactivation of CtrA and clearance of the replication block^[@CR6]^ (Fig. [1a](#Fig1){ref-type="fig"}). The CckA switch is governed by two response regulators, DivK and PleD. While DivK controls CckA activity through protein--protein interactions^[@CR7]--[@CR9]^, PleD is a diguanylate cyclase, which is responsible for the characteristic oscillation of c-di-GMP during the cell cycle^[@CR10]^. The concentration of c-di-GMP, below the detection limit in G1, increases during G1/S to reach peak levels at the onset of S-phase^[@CR11]^ where it allosterically stimulates CckA phosphatase^[@CR9]^ (Fig. [1a](#Fig1){ref-type="fig"}).

Activation of DivK and PleD is directed by the SpmX scaffolding protein, which accumulates during G1/S and recruits DivJ, the kinase of DivK and PleD, to the incipient stalked cell pole (Fig. [1a](#Fig1){ref-type="fig"})^[@CR12]^. This makes SpmX accumulation the earliest known event to trigger S-phase entry. However, it is unclear how *spmX* expression is timed during G1/S to initiate replication. Transcription of *spmX* is regulated by the response regulator TacA, which in its phosphorylated form also induces the expression of a large set of genes required for SW-to-ST cell morphogenesis^[@CR12],[@CR13]^. TacA is activated via a multistep phosphorylation cascade (Fig. [1b](#Fig1){ref-type="fig"}) consisting of the sensor histidine kinase ShkA, and the phosphotransferase protein ShpA^[@CR12],[@CR13]^. ShkA is a multidomain protein kinase with a catalytic domain (CA) that binds ATP and transfers a phosphate via the conserved His residue of the dimerization histidine-phosphotransfer domain (DHp) to a conserved Asp residue of the C-terminal receiver domain (REC2)^[@CR12],[@CR13]^ (Fig. [1b](#Fig1){ref-type="fig"}). TacA controls a large set of target genes including *staR*, which encodes a transcription factor important for stalk elongation. Thus, this phosphorelay system coordinates replication initiation with morphogenesis. In accordance, cells lacking TacA are elongated, stalk-less and show altered DNA profiles compared with wild type^[@CR13],[@CR14]^. However, the signal activating ShkA has remained unknown (Fig. [1b](#Fig1){ref-type="fig"}).

Here we demonstrate that an upshift in levels of the second messenger c-di-GMP determines precise gene expression during G1/S. A combination of genetic, biochemical and cell biology data revealed that c-di-GMP controls the ShkA-TacA pathway by directly binding to the ShkA sensor histidine kinase and strongly stimulating its kinase activity. We demonstrate that binding of c-di-GMP to a pseudo-receiver domain of ShkA abrogates ShkA auto-inhibition leading to the activation of the ShkA-TacA pathway. C-di-GMP-mediated activation of ShkA and the subsequent c-di-GMP-mediated proteolysis of ShkA together define a window of ShkA activity during the cell cycle. This window is sharpened to a narrow, G1/S-specific period by TacA degradation, which precedes the degradation of ShkA. Thus, the exact timing of G1/S-specific gene expression results from the consecutive c-di-GMP-mediated activation and degradation of ShkA-TacA phosphorylation components.

Results {#Sec2}
=======

C-di-GMP stimulates ShkA kinase activity in vivo and in vitro {#Sec3}
-------------------------------------------------------------

A *C. crescentus* strain lacking all diguanylate cyclases (cdG^0^ strain), which was generated to remove all traces of the second messenger c-di-GMP, shows strong developmental and morphological abnormalities with mutant cells being irregularly shaped, elongated and lacking all polar appendages^[@CR11]^. Because stalk biogenesis depends on an active ShkA-TacA phosphorelay (Fig. [1b](#Fig1){ref-type="fig"})^[@CR13]^, we tested if c-di-GMP controls the ShkA-TacA pathway. Expression of TacA^D54E^, a phospho-mimetic form of TacA^[@CR13]^, restored stalk biogenesis, transcription of the TacA targets *staR* and *spmX*, as well as localization of a SpmX-mCherry fusion to the stalked pole (Fig. [1c, d](#Fig1){ref-type="fig"}; Supplementary Fig. [1](#MOESM1){ref-type="media"}). *spmX* and *staR* transcription was also restored when c-di-GMP was reintroduced by expression of the heterologous diguanylate cyclase (DGC) *dgcZ* from *E. coli* in the cdG^0^ background or in a strain that lacks all DGCs and phosphodiesterases (PDE) (rcdG^0^ strain) (Fig. [1d](#Fig1){ref-type="fig"}; Supplementary Fig. [1](#MOESM1){ref-type="media"}). Phos-tag PAGE analysis revealed that TacA and ShkA were unphosphorylated in the cdG^0^ strain. This phosphorylation was restored upon expression of the constitutively active DGC PleD\*^[@CR15]^ (Fig. [1e](#Fig1){ref-type="fig"}). In contrast, expression of the heterologous phosphodiesterase PA5295 from *Pseudomonas aeruginosa*, which also lowers c-di-GMP levels, in wild-type cells reduced TacA and ShkA phosphorylation (Fig. [1f](#Fig1){ref-type="fig"}). Stalk formation is independent of the ShkA-TacA pathway when cells are grown in a low-phosphate medium^[@CR9]^. In agreement with this, a strain lacking c-di-GMP formed stalks at low-phosphate concentrations, but failed to localize DivJ (Supplementary Fig. [1](#MOESM1){ref-type="media"}). Many cells displayed bipolar stalks, indicating that at low-phosphate c-di-GMP controls stalk positioning through a pathway distinct from ShkA-TacA. Altogether, these results indicate that c-di-GMP acts upstream of and is required for the activity of the ShkA-TacA phosphorelay.

In vitro phosphorylation assays with purified ShkA or with all components of the phosphorelay demonstrated that c-di-GMP strongly and specifically stimulates ShkA autokinase activity (Fig. [1g, h](#Fig1){ref-type="fig"}; Supplementary Fig. [2a](#MOESM1){ref-type="media"}). Moreover, purified ShkA bound c-di-GMP with a K~D~ in the sub-micromolar range (Supplementary Fig. [2b](#MOESM1){ref-type="media"}). Altogether, we conclude that c-di-GMP activates the ShkA-TacA pathway by directly binding to and allosterically stimulating ShkA kinase.

C-di-GMP activates ShkA by binding to its pseudo-receiver domain {#Sec4}
----------------------------------------------------------------

We next sought to dissect the mechanism of c-di-GMP-mediated ShkA activation. We devised a genetic selection (see "Methods") to isolate *shkA* mutations that restored *spmX* expression in a rcdG^0^ background. Independent mutations were identified in two residues (D369, R371) within a short stretch of three highly conserved amino acids in the linker region between REC1 and REC2 (hereafter referred to as the "DDR" motif) (Fig. [2a](#Fig2){ref-type="fig"}; Supplementary Fig. [3](#MOESM1){ref-type="media"}). These results identified the REC1-REC2 linker region as a critical determinant of ShkA activation.Fig. 2C-di-GMP binds to the REC1 pseudo-receiver domain.**a** ShkA domain architecture drawn to scale (top) and alignment of the REC1-REC2 linker harboring the DDR motif (highlighted in green) of ShkA orthologs (bottom). Ccr, *C. crescentus*; Cse, *Caulobacter segnis*; Che, *Caulobacter henricii*; K31, *Caulobacter sp*. K31; Pzu, *Phenylobacterium zucineum*; Abi, *Asticcacaulis biprosthecium*; Aex, *Asticcaucaulis excentricus*; Bsu, *Brevundimonas subvibrioides*. Dimerization and histidine-phosphotransfer (DHp), catalytic and ATP-binding (CA) and receiver (REC1, REC2) domains are indicated. **b** Activity of the *spmX* promoter in indicated strains harboring plasmid pAK502-*spmX*. *shkA*^*D369N*^ is expressed from the native chromosomal locus. Means and standard deviations are shown (*N* = 3). **c** Phos-tag PAGE immunoblots of indicated strains producing 3xFLAG-tagged TacA or TacA^DD^ from the native locus. **d** In vitro autophosphorylation assays of ShkA and ShkA^D369N^. Top: autoradiograph; bottom: Coomassie stain. **e** β-Gal assays of Δ*shkA* mutant strains harboring plasmid pAK502-spmX and expressing different *shkA* alleles in trans from plasmid pQF with the indicated amino acid substitutions alone (WT, white bars) or in combination with D369N (blue bars). Shown are means and standard deviations (*N* = 3). **f** In vitro autophosphorylation assays of wild type or mutant ShkA with (10 µM) or without c-di-GMP. Reactions were run for 5 min. Top: autoradiograph; bottom: Coomassie stain. **g** Autoradiographs of purified ShkA and ShkA mutant variants (0.5 µM) UV-crosslinked with 10 µM \[^32^P\]c-di-GMP with or without addition of a 50-fold molar excess of non-labeled c-di-GMP. Top: autoradiograph; bottom: Coomassie stain. **h** Quantified autoradiographs of purified ShkA and ShkA^Y338A^ (0.5 µM) UV-crosslinked with increasing concentrations of \[32 P\]c-di-GMP. Shown are mean values and standard deviations (*N* = 2). **i** Autoradiographs and Coomassie stain of the same gel of purified ShkA and the isolated REC1 domain (ShkA~REC1~) (0.5 µM) after UV crosslinking with 10 µM \[^32^P\]c-di-GMP (top). Quantified autoradiographs of purified ShkA and ShkA~REC1~ (0.5 µM) after UV crosslinking with increasing concentrations of \[^32^P\]c-di-GMP (bottom). Means and standard deviations are shown (*N* = 2). **j** Cartoon and surface representation of the ShkA~REC1~ homology model with NMR chemical shift perturbations (CSPs) upon c-di-GMP binding indicated by a blue-to-yellow gradient. **k** Conservation score of ShkA orthologs (see "Methods"). Source data are provided as a Source Data file.

We further characterized the D369N variant both in a wild-type background and in a strain expressing a stabilized version of TacA (TacA^DD^), and confirmed that TacA phosphorylation levels and *spmX* transcription were restored to wild-type levels in the rcdG^0^ background harboring the *shkA*^*D369N*^ allele (Fig. [2b, c](#Fig2){ref-type="fig"}). Also, purified ShkA^D369N^ protein showed strong autophosphorylation activity even in the absence of c-di-GMP (Fig. [2d](#Fig2){ref-type="fig"}). The mutant retained its ability to bind c-di-GMP in vitro (Supplementary Fig. [2c](#MOESM1){ref-type="media"}) and could still be partially stimulated by c-di-GMP both in vivo (Fig. [2b](#Fig2){ref-type="fig"}) and in vitro (Supplementary Fig. [2d](#MOESM1){ref-type="media"}). Thus, mutations in the DDR motif uncouple ShkA activity from c-di-GMP without interfering with c-di-GMP binding.

We used the c-di-GMP independence of the D369N ShkA variant to identify residues involved in c-di-GMP binding. We reasoned that mutations in ShkA specifically interfering with c-di-GMP-mediated activation should be rescued when combined with D369N. In contrast, mutants causing more general kinase defects (ATP-binding, phosphotransfer, protein stability etc.) would not be recuperated when combined with D369N. An alignment of ShkA orthologs from *C. crescentus* and related organisms revealed a total of 25 candidate residues for c-di-GMP binding distributed throughout the entire protein (Supplementary Fig. [3](#MOESM1){ref-type="media"}). Of all the mutants that severely affected ShkA activity (Supplementary Fig. [4a, b](#MOESM1){ref-type="media"}) and that were rescued in vivo (Fig. [2e](#Fig2){ref-type="fig"}) and in vitro (Fig. [2f](#Fig2){ref-type="fig"}) when combined with D369N, only one, Y338A, in REC1, interfered with c-di-GMP binding (Fig. [2g, h](#Fig2){ref-type="fig"}), while the other mutations likely affect c-di-GMP-mediated conformational changes required for activation.

Thus, Y338 in REC1 is likely a part of the c-di-GMP binding site. Indeed, the purified REC1 domain alone was able to bind c-di-GMP, although with lower affinity than full-length ShkA (Fig. [2i](#Fig2){ref-type="fig"}). NMR spectroscopy with REC1 revealed a fold reminiscent of prototypical REC domains, except that helix α3 is not present irrespective of the presence or absence of c-di-GMP (Supplementary Fig. [4c--f](#MOESM1){ref-type="media"}). Upon the addition of c-di-GMP, REC1 shows chemical shift perturbations (CSPs), which cluster on the β5-α5 surface (Fig. [2j](#Fig2){ref-type="fig"}; Supplementary Fig. [4g](#MOESM1){ref-type="media"}). Importantly, these residues include Y338 and are well conserved (Fig. [2k](#Fig2){ref-type="fig"}; Supplementary Fig. [3](#MOESM1){ref-type="media"}). Some of the other residues implicated in c-di-GMP binding by NMR were also important for ShkA activity in vivo (Supplementary Fig. [4h](#MOESM1){ref-type="media"}). Altogether, these experiments revealed a REC1 pseudo-receiver domain of ShkA as the primary docking site for c-di-GMP, and identified residues directly involved in c-di-GMP binding and c-di-GMP-mediated activation of ShkA. In silico analysis revealed that pseudo-receiver domains, although often not annotated, are widespread among histidine kinases (Supplementary Fig. [5](#MOESM1){ref-type="media"}, Supplementary Data [1](#MOESM3){ref-type="media"}). We propose that pseudo-receiver domains have lost their original phosphotransfer function but during evolution have adopted signal perception functions and may thus represent a large class of so-far unrecognized kinase input domains.

Similar to the two identified DDR mutants, the kinase activity of ShkA is also uncoupled from c-di-GMP when conserved residues of REC2 are mutated (Supplementary Fig. [2e](#MOESM1){ref-type="media"}) or when the C-terminal REC2 domain is removed from the catalytic core (DHp, CA, and REC1 domain) (Fig. [1h](#Fig1){ref-type="fig"}). Thus, the REC2 domain and the DDR linker motif inhibit ShkA autophosphorylation, maintaining it in an inactive state. We propose that c-di-GMP binding to REC1 overrides this auto-inhibition and activates the enzyme.

C-di-GMP defines a narrow window of ShkA activity during G1/S {#Sec5}
-------------------------------------------------------------

The c-di-GMP-independent variants of ShkA allowed us to more carefully investigate the role of ShkA in the temporal control of events during G1/S. Introduction of the *shkA*^*D369N*^ allele into the rcdG^0^ strain restored SpmX protein levels, stalk biogenesis, DivJ localization to the incipient stalked pole, and normal cell morphology (Fig. [3a, b](#Fig3){ref-type="fig"}; Supplementary Fig. [6a](#MOESM1){ref-type="media"}). Of note, *shkA*^*D369N*^ failed to restore G2-specific processes in the rcdG^0^ strain like motility and type IV pili assembly (Supplementary Fig. [6b, c](#MOESM1){ref-type="media"}). Restoration of cell morphology and DivJ localization was entirely dependent on SpmX (Fig. [3b](#Fig3){ref-type="fig"}), arguing that c-di-GMP and ShkA contribute to cell cycle progression and morphogenesis via *spmX* expression control. Consistent with this notion, the *shkA*^*D369N*^ allele rescued the synthetic-lethal phenotype of a strain lacking c-di-GMP and suffering from reduced DivK levels^[@CR9]^ in a SpmX-dependent manner (Supplementary Fig. [6](#MOESM1){ref-type="media"}), indicating that ShkA influences the CckA kinase/phosphatase balance. A strain harboring the *shkA*^*D369N*^ allele prematurely produced SpmX already in newborn G1 cells (Fig. [3c](#Fig3){ref-type="fig"}). Accordingly, the *shkA*^*D369N*^ mutant exited G1 prematurely, as indicated by the strong reduction of G1 cells (Fig. [3d](#Fig3){ref-type="fig"}). Likewise, cells failed to properly arrest in G1 after entry into the stationary phase (Fig. [3d, e](#Fig3){ref-type="fig"}). Growth rate of the *shkA*^*D369N*^ mutant was not increased in either PYE or M2G medium compared with wild type, suggesting that the overall length of the cell cycle (combined G1, S, and G2 phases) is not or only marginally affected (Supplementary Fig. [6](#MOESM1){ref-type="media"}). These results support a role of c-di-GMP, and the ShkA-TacA pathway, in the timely execution of the G1/S transition.Fig. 3C-di-GMP imposes precise temporal control of TacA activity during G1/S.**a** Representative phase-contrast micrographs of indicated strains. Arrows point to stalks. The scale bar represents 4 µm. **b** Quantification of cell length and polar DivJ localization (DivJ-mCherry) of indicated strains. Median values with interquartile ranges are shown in the graph and mean values and standard deviations are indicated above the graph. The number of cells analyzed is shown in brackets. \*\*\*\* indicates a *P* value of \< 0.0001; ns, not significant (ordinary one-way ANOVA and Tukey's multiple comparison test). **c** Immunoblots of synchronized cultures of *C. crescentus* strains expressing *3xFLAG*-*shkA* or *3xFLAG*-*shkA*^*D369N*^ from the native chromosomal locus were probed with anti-FLAG, anti-TacA, anti-SpmX and anti-CtrA antibodies. **d** Analysis of chromosome content by flow cytometry of indicated strains in exponential or stationary phase after rifampicin treatment. **e** Quantification of chromosome number of indicated strains. Shown are means and standard deviations (*N* = 3). **f** Phos-tag PAGE immunoblots of synchronized cultures of strains expressing chromosomally encoded *3xFLAG*-*tacA*, *3xFLAG*-*shkA, 3xFLAG*-*tacA*^*DD*^, or *3xFLAG*-*shkA*^*DD*^ alleles were probed with anti-FLAG antibody. **g** Phos-tag PAGE immunoblots of mixed cultures of indicated mutant strains expressing *3xFLAG*-*tacA* probed with anti-FLAG antibodies. **h** Phos-tag PAGE immunoblots of mixed cultures of indicated mutant strains expressing *3xFLAG*-*shkA* probed with anti-FLAG antibodies. Source data are provided as a Source Data file.

TacA was previously shown to be degraded by the ClpXP protease, a process that requires the adapter proteins RcdA and CpdR and depends on the C-terminal Ala--Gly degradation motif of TacA^[@CR16]^. ShkA harbors the same C-terminal degradation signal and was also degraded upon S-phase entry about 10 min after the removal of TacA (Fig. [3f](#Fig3){ref-type="fig"}). When the C-terminal Ala--Gly motif was replaced by Asp residues (ShkA^DD^), ShkA and ShkA\~P were stabilized and prevailed throughout the cell cycle (Fig. [3f](#Fig3){ref-type="fig"}). Sequential degradation of TacA and ShkA may be explained by their differential requirements for protease adapters. While TacA degradation by ClpXP depends on CpdR and RcdA^[@CR16]^, ShkA degradation also requires PopA, the third member of the adapter hierarchy regulating ClpXP protease activity during the *C. crescentus* cell cycle (Fig. [3g, h](#Fig3){ref-type="fig"}). Because PopA needs to bind c-di-GMP to act as a protease adapter^[@CR17]^, the ShkA-TacA pathway is confined to G1/S by the sequential c-di-GMP-dependent activation and c-di-GMP-mediated degradation of the ShkA kinase.

The ShkA-TacA pathway limits gene expression to G1/S {#Sec6}
----------------------------------------------------

To carefully assess the contribution of ShkA activation and degradation for the temporal control of *spmX*, the *spmX* promoter was fused to the fluorescent protein Dendra2. The photoconvertible properties of Dendra2^[@CR18]^ allowed determining both "ON" and "OFF" kinetics of *spmX* promoter activity during the cell cycle (Fig. [4b](#Fig4){ref-type="fig"}; Supplementary Fig. [7a](#MOESM1){ref-type="media"}). These experiments revealed that *spmX* promoter activity peaks during G1/S roughly 15--30 min after passing through the predivisional stage (Fig. [4b](#Fig4){ref-type="fig"}). The *spmX* promoter was active in cells progressing through G1/S, but not in newborn ST progeny that reenter S-phase immediately at the end of the asymmetric cell cycle (Fig. [4a, c](#Fig4){ref-type="fig"}; Supplementary Fig. [7a--c](#MOESM1){ref-type="media"}). Stage-specific expression of *spmX* required a combination of c-di-GMP oscillations during the cell cycle and TacA degradation: expression of combinations of *dgcZ*, a gene encoding a highly active DGC from *E. coli*^[@CR19]^, and of *tacA*^*DD*^ (encoding stable TacA^[@CR16]^) and *shkA*^*D369N*^ (encoding constitutive ShkA) alleles resulted in a gradual loss of G1/S-specific *spmX* expression (Fig. [4c](#Fig4){ref-type="fig"}; Supplementary Fig. [7c](#MOESM1){ref-type="media"}). These experiments provided direct evidence that the activity of the ShkA-TacA pathway is strictly limited to G1/S and SW progeny that need to passage through the G1 phase of the cell cycle.Fig. 4Oscillation of c-di-GMP and protein degradation limit TacA activity to G1/S.**a** Time-lapse fluorescence microscopy of *C. crescentus* wild-type cells expressing *dendra2* from the *spmX* promoter. The time of photoconversion of Dendra2 (green to red) in the predivisional cell (PD) is indicated in the schematic of the *C. crescentus* cell cycle. A representative example of a dividing cell is shown below with separate green and red channels and with the ST cell pole of the PD cell marked (orange arrow). *spmX* expression (green) is restricted to the SW cell during G1/S transition (white arrows). The bar is 1 μm. **b** ON and OFF kinetics of *spmX* promoter activity during G1/S in wild-type cells harboring the *spmX-dendra2* reporter plasmid. ON kinetics were determined as outlined in **a** with cells being photoconverted before division (0 min) and the fraction of ST (gray circles) and SW cells (green circles) with induced green fluorescence plotted over time. OFF kinetics were determined by the fraction of SW cells with induced green fluorescence after photoconversion at the indicated time points during the cell cycle (blue boxes). The overlap of the two curves (green area) defines the window of *spmX* promoter activity during the cell cycle. **c** Activity of *spmX* promoter in lineages of individual *C. crescentus* cells of different strains through three consecutive generations as indicated by the schematic on the left. The projected G1/S-specific expression of *spmX* is indicated in green. For each strain 10--16 late PD harboring the *spmX-dendra2* reporter were photoconverted roughly 15 min before cell division and followed by time-lapse microscopy through three cell division events. Right: The fraction of SW and ST offspring (% of total cells analyzed) with active *spmX* promoter (green) was plotted over three generations with the *x*-axis representing generations 1--3. For experimental details and data analysis see "Methods". C-di-GMP levels were manipulated by P*lac*-driven *dgcZ* with 0.1 mM IPTG. EV, empty vector control. **d** Representative phase-contrast micrographs of strains carrying different *shkA* and *tacA* alleles encoding stabilized (*shkA*^*DD*^ and *tacA*^*DD*^) or c-di-GMP-independent (*shkA*^*D369N*^) versions of the respective proteins. The scale bar represents 4 µm.

To investigate the importance of limiting the ShkA-TacA pathway to G1/S for accurate cell cycle progression, we examined the consequences of ShkA-TacA dysregulation using stable (TacA^DD^, ShkA^DD^), or constitutively active (ShkA^D369N^) variants or combinations thereof. All alleles increased overall *spmX* expression and showed additive effects when combined (Supplementary Fig. [8a](#MOESM1){ref-type="media"}). Cell division and cell morphology were normal in all strains that either retained TacA degradation or c-di-GMP-mediated ShkA activity control. However, when mutations that stabilize ShkA or TacA were combined with a mutation constitutively activating ShkA, strains showed strong cell division and morphology aberrations, effects that were strictly dependent on an intact copy of *spmX* (Fig. [4d](#Fig4){ref-type="fig"}; Supplementary Fig. [8b](#MOESM1){ref-type="media"}). Thus, dysregulation of the SpmX morphogen leads to aberrant cell morphogenesis. Together, these experiments provide evidence that dysregulation of ShkA-TacA activity leads to severe cell cycle and morphological defects.

The diguanylate cyclase PleD activates ShkA during G1/S {#Sec7}
-------------------------------------------------------

The above data support a model in which an upshift of c-di-GMP stimulates ShkA kinase activity thereby initiating the G1/S-specific genetic program (Fig. [5a](#Fig5){ref-type="fig"}). If so, the G1/S transition should be kick-started by one of the *C. crescentus* diguanylate cyclases. Screening a *spmX-lacZ* reporter strain for transposon insertions with reduced *lacZ* expression identified mutations in *pleD*. Accordingly, a Δ*pleD* deletion strain showed strongly reduced *spmX* expression (Fig. [5b](#Fig5){ref-type="fig"}). While a second diguanylate cyclase enzyme, DgcB, had a more modest effect, *spmX* promoter activity was almost completely abolished in a Δ*pleD* Δ*dgcB* double mutant, akin to a strain lacking c-di-GMP (Fig. [5b](#Fig5){ref-type="fig"}). Thus, PleD is the major diguanylate cyclase driving the G1/S-specific transcriptional program.Fig. 5C-di-GMP-dependent ShkA activation requires PleC and PleD.**a** Model of ShkA-TacA phosphorelay activation and its contribution to G1/S transition. The upper part shows the intercalated network of kinases (PleC, DivJ, ShkA, CckA) and response regulators (PleD, TacA, DivK) that contribute to G1/S transition. HK indicates a hypothetical histidine kinase that controls the activity of PleD and possibly DivK (stippled lines) and by that acts as kick-starter for G1 exit. HK expression is postulated to be CtrA-mediated (stippled line). The initial, HK-PleD-mediated increase of c-di-GMP activates the ShkA-TacA pathway, resulting in a SpmX-DivJ-PleD-mediated further boost of c-di-GMP concentration, which activates the CckA phosphatase and PopA. Note that ShkA has a five- to tenfold higher affinity for c-di-GMP compared with CckA and PopA. The block of replication initiation by binding of activated CtrA to the chromosomal origin of replication (*Cori*) is indicated. The lower part of the graph indicates time windows of CckA kinase and phosphatase as well as TacA kinase activity. The gradual increase of c-di-GMP during G1/S is indicated. **b** Activity of the *spmX* promoter in strains harboring a *spmX'-'lacZ* reporter fusion (pAK502-*spmX*). Shown are mean values and standard deviations (*N* = 3). **c** Activity of the *tacA* promoter in strains harboring a *tacA'-'lacZ* fusion (pAK502-*tacA*). Strains with a chromosomal *pleC* deletion express wild type and mutant *pleC* alleles from plasmid pQF under control of their native promoter. PleC(F778L): Kinase−/phosphatase+ (K−P+); PleC(T614R) kinase−/phosphatase− (K−P−); - indicates the empty vector control (plasmid pQF). Shown are mean values and standard deviations (*N* = 3). **d** Immunoblots of selected strains shown in **c** probed with anti-SpmX and anti-MreB antibodies (top) or anti-PleC antibodies (bottom). **e** Immunoblots of selected strains shown in **c** probed with anti-SpmX and anti-MreB antibodies. **f** Immunoblots of indicated strains probed with anti-SpmX and anti-MreB antibodies. pPleD\* indicates a pMR20-based plasmid (pPA114-47) expressing the constitutively active, phosphorylation-independent PleD\* allele. EV denotes the empty plasmid control (pMR20). Source data are provided as a Source Data file.

PleD phosphorylation is regulated by the antagonistic ST cell-specific kinase DivJ and the SW cell-specific phosphatase PleC (Figs. [1a](#Fig1){ref-type="fig"} and [5a](#Fig5){ref-type="fig"})^[@CR8]^. However, PleC but not DivJ, was required for *spmX* expression, and *spmX* expression was restored to normal levels in a strain lacking both PleC and DivJ (Fig. [5b](#Fig5){ref-type="fig"}). This indicated that neither DivJ nor PleC is responsible for the initial activation of PleD and for ShkA stimulation, and that the role of PleC is likely indirect. PleC phosphatase was previously shown to reduce DivK phosphorylation leading to the activation of CtrA. Because *tacA* is a direct target of CtrA, it was proposed that in a *∆pleC* mutant, *spmX* expression is impaired because TacA fails to accumulate^[@CR12]^. Expression of *tacA* and *spmX* indeed required the PleC phosphatase (Fig. [5c, d](#Fig5){ref-type="fig"}). However, when the *pleC* deletion was combined with the constitutive *shkA*^*D369N*^ allele, SpmX protein levels and polar localization of DivJ, but not *tacA* expression, were fully restored (Fig. [5c, e](#Fig5){ref-type="fig"}; Supplementary Fig. [9](#MOESM1){ref-type="media"}), arguing that TacA levels are not the limiting factor in cells lacking PleC. Rather, ShkA activity and its stimulation by c-di-GMP are switched off in the Δ*pleC* mutant. Indeed, a constitutively active variant of PleD, PleD\*^[@CR15]^, restored SpmX protein levels in the Δ*pleC* mutant, an effect that was entirely dependent on ShkA (Fig. [5f](#Fig5){ref-type="fig"}). These results suggest that c-di-GMP levels are limiting in a *∆pleC* mutant. In line with this, LC-MS measurements showed that the Δ*pleC* mutant has significantly reduced c-di-GMP levels as compared with the isogenic *pleC*^+^ strain (9.5 ± 1.3 µM vs. 16.3 ± 0.5 µM; *N* = 3).

The finding that the ShkA-TacA pathway is OFF in the *∆pleC* mutant because c-di-GMP concentrations are limiting, together with the observation that PleD serves as the main c-di-GMP donor for ShkA activation, argues for the existence of an as yet unidentified PleD kinase, the expression of which will likely depend on the PleC-CckA-CtrA cascade. We speculate that activation of this kinase and its downstream target PleD represents a key event in the decision of *C. crescentus* to exit G1 (Fig. [5a](#Fig5){ref-type="fig"}).

Discussion {#Sec8}
==========

*C. crescentus* SW cells are born with low levels of c-di-GMP^[@CR11],[@CR20]^. This is imposed by two cell type-specific regulators, the phosphodiesterases PdeA^[@CR21]^ and the phosphatase PleC, which maintains the diguanylate cyclase PleD in its inactive, unphosphorylated form^[@CR8]^ (Fig. [5a](#Fig5){ref-type="fig"}). During the G1/S transition, PdeA is proteolytically removed^[@CR21]^ and PleD is activated by phosphorylation. This results in a gradual increase of c-di-GMP^[@CR11],[@CR20]^, which leads to a series of accurately timed events prompting exit from G1, cell morphogenesis and entry into S-phase. First, ShkA is allosterically activated resulting in TacA phosphorylation and the expression of a large group of G1/S-specific genes that orchestrate the morphological restructuring of the motile SW cells into sessile ST cells^[@CR13],[@CR14]^. At this stage, c-di-GMP levels are high enough to activate ShkA-TacA but have not reached the peak levels needed to trigger the CckA cell cycle switch and S-phase entry^[@CR8],[@CR9]^. This leads to the execution of the morphogenetic program before cells commit to chromosome replication and division. The next step is then catalyzed by the expression of one of the G1/S-specific proteins, the morphogen SpmX, which is responsible for the polar sequestration and activation of DivJ^[@CR12]^. This, in turn, leads to the production of more c-di-GMP via reinforced activation of PleD and, together with DivJ-mediated phosphorylation of DivK, switches CckA into a phosphatase and ultimately licenses replication initiation^[@CR7]--[@CR9]^ (Fig. [5a](#Fig5){ref-type="fig"}). ShkA binds c-di-GMP with five- to tenfold higher affinity than CckA^[@CR9],[@CR17]^ explaining how the ShkA-TacA pathway and the CckA switch can be sequentially activated. Thus, at least four kinases form a hierarchical cascade (HK→ShkA→DivJ→CckA) that is responsible for the accurate temporal control of events during G1/S. The activity and timing of this cascade is coordinated by the second messenger c-di-GMP, a stepwise increase of which enforces consecutive cell cycle steps by modulating the activity of ShkA and CckA, respectively (Fig. [5a](#Fig5){ref-type="fig"}).

By contributing to the CckA phosphatase switch via SpmX and DivJ, the ShkA-TacA pathway initiates its own termination. The CckA phosphatase activates a protease adapter cascade that includes CpdR and PopA^[@CR16]^ and that leads to the consecutive degradation of TacA and ShkA by the ClpXP protease (Fig. [5a](#Fig5){ref-type="fig"}). This negative feedback constitutes an intrinsic, self-sustained timer that shuts down ShkA-TacA activity as soon as c-di-GMP has reached peak levels required to activate the CckA phosphatase and the PopA protease adapter, thereby irreversibly committing cells to S-phase. Because TacA not only controls genes involved in cell cycle progression but also regulates morphological restructuring of the motile SW cells into sessile ST cells^[@CR13],[@CR14]^, accurate temporal control of this pathway secures the tight coordination between replicative and behavioral processes.

Our results show that the diguanylate cyclase PleD is largely responsible for the c-di-GMP upshift during G1-S transition. We postulate that the initial event leading to PleD activation during G1/S must be executed by a kinase other than DivJ or PleC, and that DivJ is part of a positive feedback loop that reinforces PleD activity upon S-phase entry (Fig. [5a](#Fig5){ref-type="fig"}). Although the nature of this kinase is currently unknown, we speculate that its expression or activity is CtrA-dependent and that it plays a key role in orchestrating exit from G1 as it may not only serve to activate PleD and provide the initial boost of c-di-GMP but may also contribute to the activation of DivK, a factor required for the CckA kinase/phosphatase switch. The essential nature of DivK but not of DivJ, its only known activating kinase, argues for regulatory redundancy in the upstream components required to boost DivK phosphorylation during G1/S (Fig. [5a](#Fig5){ref-type="fig"}).

We postulate that in its default state, the ShkA kinase is inhibited by the C-terminal REC2 domain and that c-di-GMP binding liberates the kinase by interfering with this off-state conformation. A ShkA variant lacking the REC2 domain is active without c-di-GMP^[@CR13]^. Similarly, mutations of residues important for REC2 function lead to constitutive, c-di-GMP-independent autokinase activity. Thus, the conserved DDR motif in the REC1-REC2 linker likely serves to lock ShkA in the inactive state when no c-di-GMP is present. REC2 may be closely tethered to REC1 in the inactive state through an interaction of the DDR linker motif with REC1, a conformation that may prevent the productive interaction of the catalytic CA with the DHp domain. We hypothesize that binding of c-di-GMP to REC1 interferes with this tethering, thereby liberating REC2 and facilitating the productive interaction between CA and DHp for autophosphorylation and eventually for phosphotransfer between DHp and REC2. This model is strongly supported by an accompanying structural analysis of ShkA^[@CR22]^.

These findings demonstrate that degenerate REC domains, also called pseudo-receiver domains, can function as docking sites for small regulatory molecules. Hybrid histidine kinases with pseudo-receiver domains located between the CA and the phosphorylated receiver domain are widespread in bacteria and include the well-studied virulence factors of the GacS/BarA family^[@CR23],[@CR24]^ or the global stress regulator RcsC^[@CR25],[@CR26]^ (Supplementary Fig. [5](#MOESM1){ref-type="media"}). For instance, the pseudo-receiver of RcsC can only be recognized by structural comparison^[@CR25]^, arguing that primary structure-based searches largely underestimate the actual number of these modules. It is possible that pseudo-receiver domains generally serve as binding sites for metabolites or small signaling molecule thereby modulating kinase or phosphatase activity of such key bacterial regulators. In line with this, prominent examples of kinases harboring pseudo-receiver domains like GacS in *P. aeruginosa* or BarA and RcsC in *E. coli* are part of complex signaling cascades that globally regulate bacterial physiology and behavior. Careful scrutiny of the exact function of these domains will be essential to improve our understanding of such important regulatory nodes in bacteria.

Methods {#Sec9}
=======

Growth conditions {#Sec10}
-----------------

*Caulobacter crescentus* was grown in PYE (0.2% \[w/v\] bacto peptone, 0.1% \[w/v\] yeast extract, 0.8 mM MgSO~4~, 0.5 mM CaCl~2~) or defined M2G (12.2 mM Na~2~HPO~4~, 7.8 mM KH~2~PO~4~, 9.3 mM NH~4~Cl, 0.5 mM MgSO~4~, 0.5 mM CaCl~2~, 20 µM FeSO~4~, 0.2% \[w/v\] [d]{.smallcaps}-glucose) medium at 30 °C. Growth in low-phosphate medium (PYETris) was performed by replacing the phosphate buffer components in M2G with 20 mM Tris-HCl (pH 7.0)^[@CR12],[@CR29]^. Standard plates contained 1.5% \[w/v\] agar. Motility was assayed on PYE plates containing 0.3% agar. *Escherichia coli* DH5α, DH10B, or TOP10 were used for cloning and were routinely cultivated in LB-Miller at 37 °C. When appropriate, media were supplemented with antibiotics at the following concentrations unless stated otherwise (liquid/solid media for *C. crescentus*; liquid/solid media for *E. coli*; in μg ml^−1^): kanamycin (5/20; 30/50), oxytetracycline (2.5/5; 12.5/12.5), chloramphenicol (1/2; 20/30), gentamycin (1/5; 20/20), spectinomycin (25/50; −/−), streptomycin (5/5; −/−), ampicillin (−/−; 100/100), nalidixic acid (15/20; −/−). Isopropy-β-D-thiogalactopyranoside (IPTG), 4-hydroxy-3-methoxybenzoic acid (vanillate), and xylose stocks were prepared in ddH~2~O at concentrations of 1 M, 200 mM, and 20% \[w/v\], respectively, and used at final concentrations of 300 µM, 250 µM, and 0.2% in *C. crescentus*, if not otherwise stated. 4-isopropylbenzoic acid (cumate) stocks (100 mM) were prepared in 100% ethanol and used at a final concentration of 100 µM. Note that for experiments in which *shkA* alleles were provided on plasmid pQF in trans no cumate was present since already leaky expression of the wild-type allele could complement the ∆*shkA* null mutant phenotype.

Strains and plasmids {#Sec11}
--------------------

Plasmids are listed in Supplementary Data [2](#MOESM4){ref-type="media"}. Oligonucleotides used for plasmid construction were purchased from Sigma and are listed in Supplementary Data [3](#MOESM5){ref-type="media"}. Plasmids were constructed as follows:

pAK503: *nptII* without RBS and start codon was PCR-amplified from pAK405 using primers 8959/9495, the product was digested with *Bsr*GI/*Xba*I and cloned into pAK501 cut with *Acc*65I/*Xba*I.

pAK502-*tacA*: the *spmX* promoter and part of the codon sequence were PCR-amplified from *C. crescentus* gDNA using primers 10015/10016, the product was digested with *Xba*I/*Kpn*I and cloned into pAK502 digested with the same enzymes.

pAK502-*spmX*: the *spmX* promoter and part of the codon sequence were PCR-amplified from *C. crescentus* gDNA using primers 8966/9064, the product was digested with *Xba*I/*Kpn*I and cloned into pAK502 digested with the same enzymes.

pAK503-*spmX*: the *spmX* promoter and part of the codon sequence were PCR-amplified from *C. crescentus* gDNA using primers 8966/9064, the product was digested with *Xba*I/*Kpn*I and cloned into pAK503 digested with the same enzymes.

pNPTStet: *tetA* and *tetR* were PCR-amplified from pQF using primers 9552/9553, the product was digested with *Spe*I/*Nde*I and cloned into pNPTS138 digested with *Ase*I/*Xba*I.

pNPTStet-*ampG*: part of *ampG* located downstream of *shkA* was PCR-amplified from *C. crescentus* gDNA with primers 9554/9555, the product was digested with *Spe*I/*Kpn*I and cloned into pNPTStet digested with the same enzymes.

pET28a-*shkA*: *shkA* was PCR-amplified from *C. crescentus* gDNA with primers 9745/9746, the product was digested with *Nde*I/*Eco*RI and cloned into pET28a digested with the same enzymes.

pET28a-*shkA(D369N)*: *shkA(D369N)* was amplified from *C. crescentus* strain UJ9618 by colony-PCR using primers 9745/9746, the product was digested with *Nde*I/*Eco*RI and cloned into pET28a digested with the same enzymes.

pQF-*shkA*: *shkA* was PCR-amplified from *C. crescentus* gDNA with primers 9745/9746, the product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(D369N)*: *shkA(D369N)* was amplified from *C. crescentus* strain UJ9618 by colony-PCR using primers 9745/9746, the product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R26A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9904/9905. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(H61A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9968/9969. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R74A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9970/9971. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI. This *shkA* allele contains a second mutation, A451V.

pQF-*shkA(W113A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9906/9907. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI. This *shkA* allele contains a second mutation, A451V.

pQF-*shkA(D125N)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10009/10010. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R128A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10005/10006. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R130A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10007/10008. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R128A, R130A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9908/9909. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R177A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9910/9911. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI. This *shkA* allele contains a second mutation, P233L.

pQF-*shkA(F230A, F234A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9972/9973. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(D297N)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9974/9975. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(P321A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10013/10014. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R324A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9912/9913. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(D325N)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10011/10012. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(I327A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9976/9977. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI. This *shkA* allele contains a second mutation, A451V.

pQF-*shkA(Y338A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9978/9979. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(R344A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9914/9915. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI. This *shkA* allele contains a second mutation, A451V.

pQF-*shkA(E402A, G403A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9980/9981. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(C404A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9986/9987. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(D430N)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10028/10029. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(D465A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9982/9983. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI. This *shkA* allele contains a second mutation*, A451V*.

pQF-*shkA(C469A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9984/9985. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI. This *shkA* allele contains a second mutation, *A451V*.

pQF-*shkA(K341)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11171/11172. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(P342A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11173/11174. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(L343A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11175/11176. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(I340A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11177/11178. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(L338A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11179/11180. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(G337A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11181/11182. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(K331A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11183/11184. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(S347A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11185/11186. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(Q351A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 11187/11188. The product was digested with *Nde*I/*Eco*RI and cloned into pQF digested with *Ase*I/*Eco*RI.

pQF-*shkA(D369N, H61A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(H61A)* by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pQF-*shkA(D369N, R128A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(R128A)* by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pQF-*shkA(D369N, R130)*: a fragment harboring part of *shkA* was released from pQF-*shkA(R130A)* by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pQF-*shkA(D369N, R128A, R130A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(R128A, R130A)* by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pQF-*shkA(D369N, F230A, F234A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(F230A, F234A)* by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pQF-*shkA(D369N, R128A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(R128A)* by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pQF-*shkA(D369N, R324A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(R324A*) by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pQF-*shkA(D369N, Y338A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(Y338A)* by digestion with *Spe*I/*Pst*I and cloned into pQF-*shkA(D369N)* digested with the same enzymes.

pET28a-*shkA(D430N)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10028/10029. The product was digested with *Nde*I/*Eco*RI and cloned into pET28a digested with *Nde*I/*Eco*RI.

pET28a-*shkA(E386Q, D387N)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10026/10027. The product was digested with *Nde*I/*Eco*RI and cloned into pET28a digested with *Nde*I/*Eco*RI.

pET28a-*shkA(K480R)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 10024/10025. The product was digested with *Nde*I/*Eco*RI and cloned into pET28a digested with *Nde*I/*Eco*RI.

pET28a-*shkA(R324A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(R324A)* by digestion with *Asc*I/*Pst*I and cloned into pET28a-*shkA* digested with the same enzymes.

pET28a-*shkA(D369N, R324A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(R324A)* by digestion with *Asc*I/*Pst*I and cloned into pET28a-*shkA(D369N)* digested with the same enzymes.

pET28a-*shkA(Y338A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(Y338A)* by digestion with *Asc*I/*Pst*I and cloned into pET28a-*shkA* digested with the same enzymes.

pET28a-*shkA(D369N, Y338A)*: a fragment harboring part of *shkA* was released from pQF-*shkA(Y338A)* by digestion with *Asc*I/*Pst*I and cloned into pET28a-*shkA(D369N)* digested with the same enzymes.

pET28a-*shkA(R128A, R130A)*: the mutant allele was generated by SOE-PCR using pET28a-*shkA* as template and flanking primers 669/670 and mutagenic primers 9908/9909. The product was digested with *Nde*I/*Eco*RI and cloned into pET28a digested with the same enzymes.

pET28a-*shkA-REC1*: a fragment of *shkA* encoding REC1 was PCR-amplified from *C. crescentus* gDNA with primers 10862/10866, the product was digested with *Nde*I/*Kpn*I and cloned into pUC18 digested with the same enzymes. A *Nde*I/*Eco*RI from the resulting plasmid was subcloned into pET28a digested with the same enzymes.

pQF-*pleC*: a DNA fragment including *pleC* ORF and the mapped *pleC* promoter as PCR-amplified from plasmid pJS14-*pleC* with primers 10781/10783, the product was digested with *Spe*I/*Kpn*I and cloned into pQF digested with the same enzymes.

pQF-*pleC(K−P−)*: a DNA fragment including *pleC(T614R)* ORF and the mapped *pleC* promoter as PCR-amplified from plasmid pJS14-*pleC(T615R)* with primers 10781/10783, the product was digested with *Spe*I/*Kpn*I and cloned into pQF digested with the same enzymes.

pQF-*pleC(K−P+)*: a DNA fragment including *pleC*(F778L) ORF and the mapped *pleC* promoter as PCR-amplified from plasmid pJS14-*pleC*(F778L) with primers 10781/10783, the product was digested with *Spe*I/*Kpn*I and cloned into pQF digested with the same enzymes.

p*divJ-mCherry*: the 3′ part of *divJ* was PCR-amplified from *C. crescentus* gDNA with primers 10205/10206, the product was digested with *Kpn*I/*Age*I and cloned into pCHYC-4 digested with the same enzymes.

pNPTS138-Δ*tacA*: two DNA fragments flanking the *tacA* ORF were PCR-amplified from *C. crescentus* gDNA. Fragment 1 was amplified with primers 6535/6098, then digested with *Pst*I/*Kpn*I. Fragment 2 was amplified with primers 6099/6536, then digested with *Kpn*I/*Eco*RI. The two fragments were ligated to pNPTS138 digested with *Pst*I/*Eco*RI.

pNPTS138-Δ*shkA*: two DNA fragments flanking the *shkA* ORF were PCR-amplified from *C. crescentus* gDNA. Fragment 1 was amplified with primers 6085/6086, then digested with *Pst*I/*Kpn*I. Fragment 2 was amplified with primers 6087/6088, then digested with *Kpn*I/*Eco*RI. The two fragments were ligated to pNPTS138 digested with *Pst*I/*Eco*RI.

pNPTS138-*3xFLAG-tacA*: the upstream region of the *tacA* ORF was PCR-amplified from *C. crescentus* gDNA with primers 6438/6439 (fragment 1). A 5′ part of *tacA* was PCR-amplified from *C. crescentus* gDNA with primers 6440/7604 (fragment 2), and then used as a template with primers 6441/7604 to insert the coding sequence of the 3xFlag-Tag (fragment 3). SOE-PCR was performed with fragment 1 and 3 as template and primers 6438/7604. The resulting product was then digested with *Pst*I/*Eco*RI and ligated into pNPTS138 digested with the same enzymes.

pNPTS138-*3xFLAG-shkA*: the upstream region of the *shkA* ORF was PCR-amplified from *C. crescentus* gDNA with primers 6442/6443 (fragment 1). A 5′ part of *shkA* was PCR-amplified from *C. crescentus* gDNA with primers 6444/7605 (fragment 2), and then used as a template with primers 6445/7605 to insert the coding sequence of the 3xFlag-Tag (fragment 3). SOE-PCR was performed with fragment 1 and 3 as template and primers 6442/7605. The resulting product was then digested with *Pst*I/*Eco*RI and ligated into pNPTS138 digested with the same enzymes.

pNPTS138-*shkA(DD)*: the 5′ region of *shkA* was PCR-amplified from *C. crescentus* gDNA with primers 8169/8170 (fragment 1). The downstream region of the *shkA* ORF was PCR-amplified from *C. crescentus* gDNA with primers 8171/8172 (fragment 2). SOE-PCR was performed with the two fragments as template and primers 8169/8172. The resulting product was then digested with *Bam*HI/*Eco*RI and ligated into pNPTS138 digested with the same enzymes.

pNPTS138-*tacA(DD)*: the 5′ region of *tacA* was PCR-amplified from *C. crescentus* gDNA with primers 7925/7716 (fragment 1). The downstream region of the *tacA* ORF was PCR-amplified from *C. crescentus* gDNA with primers 7717/7718 (fragment 2). SOE-PCR was performed with the two fragments as template and primers 7925/7718. The resulting product was then digested with *Hind*III/*Eco*RI and ligated into pNPTS138 digested with the same enzymes.

pNPTS138-*tacA(D54E)*: the mutant allele was generated by SOE-PCR using *C. crescentus* gDNA as template and flanking primers 7958/7961 and mutagenic primers 7959/7960. The product was digested with *Pst*I/*Eco*RI and cloned into pNPTS138 digested with the same enzymes.

pNPTS138-Δ*spmX*: two DNA fragments flanking the *spmX* ORF were PCR-amplified from *C. crescentus* gDNA. Fragment 1 was amplified with primers 7268/7269, fragment 2 was amplified with primers 7270/7271. The two fragments were joined by SOE-PCR using primers 7268/7271, digested with *Pst*I/*Eco*RI, and ligated into pNPTS138 digested with the same enzymes.

pNPTS138-Δ*CC0168*: the region upstream of CC0168 was amplified from *C. crescentus* NA1000 gDNA with primer pairs 3490 and 3491. The PCR product was cloned into pGEM-T Easy, sequenced, and cut out with *Hind*III and *Kpn*I. The region downstream of CC0168 was amplified from *C. crescentus* NA1000 gDNA with primer pairs 3492 and 3493. The PCR product was cloned into pGEM-T Easy, sequenced and cut out with *Bam*HI and *Kpn*I. Both cut PCR products were ligated in a triple ligation with pNPTS138 digested with *HindI*II and *Bam*HI.

pET28a-*His*-*shkA*: *shkA* was PCR-amplified from *C. crescentus* gDNA with primers 5988/5486, the product was digested with *Nde*I/*Hind*III and cloned into pET28a digested with the same enzymes.

pET28a-*His*-*shpA*: *shpA* was PCR-amplified from *C. crescentus* gDNA with primers 6015/6016, the product was digested with *Hind*III/*Eco*RI and cloned into pET28a digested with the same enzymes.

pET28a-*His*-*tacA-RD*: the sequence of *tacA* encoding the receiver domain was PCR-amplified from *C. crescentus* gDNA with primers 7925/6013, the product was digested with *Hind*III/*Eco*RI and cloned into pET28a digested with the same enzymes.

pET32b-*Trx-His-shkA-HK*: the sequence of *shkA* encoding the kinase catalytic core including the REC1 domain was PCR-amplified from *C. crescentus* gDNA with primers 6110/6011, the product was digested with *Hind*III/*Eco*RI and cloned into pET32b digested with the same enzymes.

pET32b-*Trx-His-shkA-RD2*: the sequence of *shkA* encoding the REC2 domain was PCR-amplified from *C. crescentus* gDNA with primers 6109/6009, the product was digested with *Hind*III/*Eco*RI and cloned into pET32b digested with the same enzymes.

pMT687-*tacA*: *tacA* was PCR-amplified from *C. crescentus* gDNA with primers 5487/5490, the product was digested with *Nde*I/*Kpn*I and cloned into pMT687 digested with the same enzymes.

pMT687-*tacA(D54E)*: the mutant allele was generated by SOE-PCR using *C. crescentus* gDNA as template and flanking primers 5487/5490 and mutagenic primers 5488/5489. The product was digested with *Nde*I/*Kpn*I and cloned into pNPTS138 digested with the same enzymes.

pQF-*PA5295*: *PA5295* was PCR-amplified from pRV-*PA5295* with primers 8974/8975, the product was digested with *Hind*III/*Kpn*I and cloned into pMT687 digested with the same enzymes.

pQF-*PA5295(AAL)*: *PA5295(AAL)* was PCR-amplified from pRV-*PA5295(AAL)* with primers 8974/8975, the product was digested with *Hind*III/*Kpn*I and cloned into pMT687 digested with the same enzymes.

pRKlac290-*spmX*: the promoter region of *spmX* was PCR-amplified from *C. crescentus* gDNA with primers 6864/6865. The resulting product was digested with *Eco*RI/*Pst*I and ligated into pRKlac290 digested with the same enzymes.

pRKlac290-*staR*: the promoter region of *staR* was PCR-amplified from *C. crescentus* gDNA with primers 6621/6622. The resulting product was digested with *Eco*RI/*Pst*I and ligated into pRKlac290 digested with the same enzymes.

pAH10: pUC19 was digested with *Hind*III and *Pci*I to integrate the following annealed oligos 5786/5903/5904/5905 downstream of the MCS.

pAH87: pMT375 was digested with *Xba*I and its insert was replaced with the *Nsi*I-*Pac*I cassette of pAH10 amplified with 7284 and 7287 digested with *Nhe*I/*Spe*I.

pAH99: *dendra2* was PCR-amplified from pDHL851 using primers 7503 and 7507, which also introduced a stop codon and the RBS of pQE70 upstream of *dendra2*. The product was digested with *Hind*III and *Pac*I and ligated into pAH87 digested with the same restriction enzymes.

pAH111: the promoter region of *spmX* was PCR-amplified from *C. crescentus* gDNA with primers 6864 and 7512, digested with *Eco*RI/*Hind*III and ligated into pAH99 digested with the same enzymes.

pAH139: *dendra2-ssrA* was generated by PCR from pDHL851 with primers 7503 and 6478. The resulting product was digested with *Hind*III/*Xho*I and ligated into pAH111 digested with the same enzymes.

Plasmid was delivered into *C. crescentus* by electroporation or triparental mating using LS980 as helper strain. φCR30 was used for generalized transduction^[@CR27]^. Strains are listed in Supplementary Data [4](#MOESM6){ref-type="media"}. In general, *C. crescentus* mutant strains were constructed by a two-step homologous recombination selection/counterselection procedure using pNPTS138. Alternatively, pNPTS138-based plasmids used for construction of a specific mutant strain were first integrated in this strain and then the mutation was moved into a clean background using φCR30-mediated generalized transduction, followed by resolution of the merodiploid by counterselection on PYE plates containing 0.3% \[w/v\] sucrose.

Synchronization {#Sec12}
---------------

Strains were grown overnight in 5 ml PYE supplemented with appropriate antibiotics and inducers in a roller drum at 30 °C. The next day, cultures were diluted 20-fold in 25 ml M2G and allowed to grow on a rocking shaker at 30 °C until they reached an OD~660~ of 0.4--0.6. These cultures were then subcultured in 300 ml M2G such that the cultures reached an OD~660~ of 0.6 after overnight incubation on a rocking shaker (160 rpm) at 30 °C. Cells were harvested (5000 *×* *g*, 10 min, 4 °C), the supernatant was aspirated, cells were resuspended in 40 ml cold phosphate buffer (12.3 mM Na~2~HPO~4~, 7.8 mM KH~2~PO~4~) or in cold M2G for experiments shown in Fig. [3c](#Fig3){ref-type="fig"} and kept at 4 °C for the rest of the procedure. 20 ml cold Ludox were added and the suspension mixed thoroughly before being transferred to precooled glass Corex tubes and spun to separate the swarmer from the stalked cells (9780 *×* *g*, 35 min, 4 °C). The top layer of cells was aspirated, the swarmer band moved to a clean precooled Corex tube and washed twice with 30 ml of either cold phosphate buffer or M2G (see above) by centrifugation (8000 *×* *g*, 10 min, 4 °C). Cells were released to a flask with pre-warmed M2G at an OD~660~ of \~0.3 and incubated in a water bath (30 °C, 150 rpm). Samples were taken at indicated time points in precooled tubes and harvested at max. speed using a cooled table-top centrifuge. The pellets were immediately snap-frozen in liquid nitrogen and stored at −20 °C until further processing.

Phos-tag PAGE {#Sec13}
-------------

Samples from mixed cultures grown in PYE were taken in exponential phase, and sampling of synchronized cultures is described above. An equivalent of 0.5 ml cell culture at an OD~660~ of 0.5 was harvested by centrifugation in a table-top centrifuge at max speed and the pellets were snap-frozen in liquid nitrogen and stored at −20 °C. Cells were lysed in 100 µl lysis buffer (5 ml contain: 10 mM Tris-HCl pH 7.5, 4% SDS, 1 PhosSTOP tablet \[Roche\], a scoop of DNase I \[NEB\]) for 5 min at room temperature. After spinning the samples for 5 min at max speed at room temperature in a table-top centrifuge, 80 µl of the cell lysate was taken up in 120 µl 1.6X SDS sample buffer (0.1 M Tris pH 6.8, 5% \[v/v\] glycerol, 0.2% \[w/v\] SDS, 1% \[v/v\] β-mercaptoethanol, 0.025% \[w/v\] bromophenol blue) and kept on ice. Subsequently, 20 µl of sample were run on 12% SDS-PAGE gels supplemented with 100 µM MnCl~2~ and 50 µM Phos-tag acrylamide compound (Wako) for 4--5 h at 100 V at 4 °C. Subsequent immunoblotting was performed as described below.

Immunoblotting {#Sec14}
--------------

Samples from mixed cultures grown in PYE were taken in exponential phase (OD~660~ of 0.3--0.4) and cells were harvested by centrifugation (max speed, 1 min, room temperature) in a table-top centrifuge. Sampling of synchronized cultures is described above. Pellets were resuspended in 1X SDS sample buffer (62.5 mM Tri-HCl pH 6.8, 10% \[v/v\] glycerol, 2% \[w/v\] SDS, 5% \[v/v\] β-mercaptoethanol, 0.001% \[w/v\] bromophenol blue) and boiled for 5--10 min before being run on 10--12.5% SDS-PAGE or precast Mini-Protean TGX (Biorad) gels. Proteins were transferred from SDS-PAGE gels to PVDF-membranes (Immobilon-P, Millipore 0.45 µm) in transfer buffer (for 1 l: 3.03 g Tris base, 14.4 g glycine, 20% \[v/v\] ethanol, ddH~2~O) using a Biorad semi-dry system (24 V, 300 mA, 30 min) or a Biorad wet blot system (100 V, 1 h, 4 °C) (Fig. [3c](#Fig3){ref-type="fig"}). For immunoblotting with Phos-tag gels, gels were kept at 4 °C and washed successively for 10 min with transfer buffer containing 10 mM EDTA and transfer buffer containing 0.1% (w/v) SDS, and transfer to PVDF-membranes (Immobilon-P, Millipore, 0.45 µm) was done using a Biorad wet blot system (80 V, 120 min, 4 °C). After transfer, membranes were blocked by incubation with blocking buffer for 1 h at room temperature. Blocking buffer was 1X PBS (137 mM NaCl, 27 mM KCl, 81 mM Na~2~HPO~4~, 18 mM KH~2~PO~4~) containing 0.1% (v/v) Tween20 and 5% (w/v) skimmed milk powder (for experiments shown in Fig. 3c) or TBST (20 mM 1 M Tris-HCl pH 7.5, 150 mM 5 M NaCl, 0.1% \[v/v\] Tween20) containing 5% skimmed milk powder (all other experiments). After blocking, membranes were incubated with the primary antibody in blocking buffer for 1 h at room temperature or overnight at 4 °C, followed by three washes in blocking buffer (5 min, room temperature) and incubation with the secondary antibody in blocking buffer for 1 h at room temperature. Membranes were washed three to four times with blocking buffer and three times in 1X PBS (for experiments shown in Fig. 3c) before addition of ECL detection reagent (KPL LumiGLO or LumiGLO Reserve, SeraCare Life Sciences). Chemiluminescence was detected using a Fujifilm LAS-4000 Imager (Fuji) with automatic exposure time determination or by exposure of membranes to X-ray films (Fujifilm). Primary antibodies were used at the following dilutions: α-MreB (1:20,000) (a gift from Régis Hallez), α-TacA (1:15,000)^[@CR12]^, α-SpmX (1:10,000)^[@CR12]^, α-PleC (1:5000)^[@CR28]^, α-CtrA (1:5000)^[@CR29]^, M2 α-FLAG (1:10,000) (Sigma). Secondary antibodies HRP-conjugated rabbit anti-mouse and swine anti-rabbit (Dako Cytomation, DK) were used at a 1:10,000 dilution.

Microscopy and image analysis {#Sec15}
-----------------------------

Cultures were grown in PYE and imaged in exponential phase (OD~660~ of 0.3--0.4) on 1% agarose PYE pads. Microscopy images were acquired using softWoRx 6.0 (GE Healthcare) on a DeltaVision system (GE Healthcare), equipped with a pco.edge sCMOS camera, and an UPlan FL N 100×/1.30 oil objective (Olympus). DivJ-mCherry localization was analyzed using Fiji software package^[@CR30]^ with the MicrobeJ plugin^[@CR31]^. Oufti^[@CR32]^ was used to quantify cell length and data were analyzed in Prism 7 (GraphPad) with statistical testing using ordinary one-way ANOVA and Tukey's multiple comparison test. SpmX-mCherry localization and stalk formation (Supplementary Fig. [1](#MOESM1){ref-type="media"}) was analysed manually.

Time-lapse microscopy and image analysis {#Sec16}
----------------------------------------

For Fig. [4](#Fig4){ref-type="fig"} and Supplementary Fig. [7](#MOESM1){ref-type="media"} *spmX* promoter activity during the cell cycle of single cells of *C. crescentus* wild type and selected mutants was analyzed using P~*spmX*~-Dendra2 and time-lapse microscopy. Strains were grown overnight in 5 ml PYE supplemented with appropriate antibiotics in a roller drum at 30 °C. On the day of the experiment, these cultures were diluted 50-fold in 5 ml PYE supplemented with 2.5 µg ml^−1^ oxytetracycline and if appropriate with 0.1 mM IPTG and allowed to grow in a roller drum at 30 °C until they reached an OD~660~ of 0.2. Cells were mounted on 1% PYE medium agar pads containing appropriate supplements sealed with a double layer of gene frames (Thermo Fisher Scientific; 1.7 × 2.8 cm) and subjected to time-lapse microscopy using softWoRx 6.0 (GE Healthcare) on a DeltaVision system (GE Healthcare), equipped with a pco.edge sCMOS camera, and an UPlan FL N 100×/1.30 oil objective (Olympus) using 0.3 s exposure time for phase-contrast, FITC and TRITC channels and a frame rate of 1 frame/15 min for different amounts of time.

For Fig. [4b, c](#Fig4){ref-type="fig"}, Supplementary Fig. [7](#MOESM1){ref-type="media"}, green Dendra2 was irreversibly photoconverted to red in the latest detectable predivisional stage 15 min before the first visible cell separation and birth of the swarmer cell using 2 s UV light (DAPI channel) leading to a conversion efficiency from green to red between 62--75%. Image processing and analysis was done using the Fiji software package^[@CR30]^. From every predivisional cell and its offspring (swarmer and stalked cell) the total cell fluorescence and cell area was manually measured for every time point over the course of one cell cycle and if appropriate for up to three consecutive cell cycles and the integrated density (mean intensity normalised to cell area) determined. In case of time point 0 (predivisional cell after photoconversion), the mean intensity of the predivisional was normalised to the area of the swarmer or stalked cell. Integrated density values were then normalised for background fluorescence to obtain normalised fluorescence values over the cell cycle, plotted as arbitrary units (A.U.) in Supplementary Fig. [7](#MOESM1){ref-type="media"}.

In order to determine the fraction of cells with induced *spmX* promoter activity in Fig. [5c](#Fig5){ref-type="fig"}, for individual cells the mean of all normalised fluorescence values over one cell cycle was calculated. If the mean normalised fluorescence was above 150 A.U., cells were scored as showing induced P*spmX* activity; if below 150 A.U. then cells were scored as non-induced.

In Fig. [4c](#Fig4){ref-type="fig"} normalised fluorescence values over the cell cycle of each cell type were set relative to the value of the late predivisional cell after photoconversion (*t*~0~ = 1). Green Dendra2 was irreversibly photoconverted to red only once in the latest detectable predivisional stage 15 min before the first visible cell separation and birth of the swarmer cell of generation 1. Image analysis was done as described above. Normalised fluorescence values of each cell type over each of the three cell cycles were set relative to the first late predivisional cell after photoconversion. The slope of relative fluorescence was determined over the course of one cell cycle and cells were scored as showing induced activity if the slope ≥0.19 or as not showing activity if the slope ≤0.19. The fraction of cells with induced *spmX* promoter activity was then calculated and plotted.

The ON kinetics of P~*spmX*~ activity in Fig. [4b](#Fig4){ref-type="fig"} was determined as following: Dendra2 was photoconverted once using 2 s UV light (DAPI channel) in the latest detectable predivisional stage 15 min before the first visible cell separation and birth of the swarmer cell. Cells were normalized and evaluated as above. The time of the first visible increase of cell fluorescence in the swarmer cell (green line) and the stalked cell (gray line) cells with slope ≥0.075 was plotted as fraction of cells with induced *spmX* promoter activity over time. For inferred OFF kinetics (blue dashed line), cells at different cell cycle stages were photoconverted once using 2 s UV light (DAPI channel), normalized as above and the increase of fluorescence within 15-min intervals was determined using the first time point after visible cell separation as reference. Fraction of cells scored as having induced *spmX* promoter activity over the cell cycle was plotted over time. Results were plotted using Prism 7 (GraphPad).

β-Galactosidase assays {#Sec17}
----------------------

For β-galactosidase assays strains harboring pAK502-based *lacZ* reporter plasmids were grown in 2 ml PYE supplemented with chloramphenicol and additional antibiotics as appropriate overnight at 30 °C in a drum roller and diluted the next day 20-fold in 2 ml of the same medium, followed by further incubation for an additional 4.5 h under the same conditions before sampling. β-Galactosidase assays were performed according to Miller^[@CR33]^. For β-galactosidase assays strains harboring pRKlac290-based plasmids were grown overnight in 5 ml PYE supplemented with the appropriate antibiotics in a roller drum at 30 °C. On the day of the experiment, these cultures were diluted 20-fold in 5 ml PYE supplemented with appropriate antibiotics and allowed to grow in a roller drum at 30 °C until they reached an OD~660~ of 0.3--0.54. 1.8 ml culture was spun and the pellet resuspended in 1.8 ml Z-buffer (0.06 M Na~2~HPO~4~, 0.04 M NaH~2~PO~4~, 0.01 M KCl, 0.001 M MgSO~4~, 0.05 M β-mercaptoethanol) of which 0.8 ml were used for OD~660~ measurements and 1 ml transferred to a chloroform-stable Eppendorf tube. Subsequently, 100 µl 0.1% SDS and 20 µl chloroform were added. Samples were vortexed for 10 s and incubated at room temperature for 30--60 min. From the top aqueous layer of the mixture three times 200 µl (three technical replicates) were transferred to a 96-well plate, 25 µl ONPG (4 mg ml^−1^ in Z-buffer) were added to each well and consumption of ONPG was followed at 405 nm using a BioTek Instruments EL800 plate reader (20 reads at the fastest interval). β-galactosidase activity was calculated as the initial slope of the increase of OD~405~ over time at a linear range and corrected for the OD~660~ and volume. Activities were normalized to the activity of a wild-type strain that was included in all assays.

Flow cytometry {#Sec18}
--------------

Cultures were inoculated from a fresh colony and strains were grown in 2 ml PYE at 30 °C in a drum roller 20 h (stationary phase) or diluted back 20-fold in 2 ml of the same medium after overnight incubation, followed by incubation for an additional 4.5 h (exponential phase). Rifampicin was added to cultures at a final concentration of 25 µg ml^−1^ and cultures were incubated for 2 h under the same conditions before cells were being fixed in cold 70% ethanol. Cells were collected by centrifugation, resuspended in 0.5 ml FACS buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 50 mM sodium citrate, 0.01% \[v/v\] TritonX-100) containing 2.5 µl RNaseA solution (Sigma) and incubated at room temperature for 30 min, after which 50 µl were transferred to 1 ml FACS buffer containing 1.5 µl YO-PRO-1 iodide (Thermo Fisher Scientific) and incubated for 2 h at room temperature in the dark. Data were acquired using a FACS Canto II (BD Biosciences) with \>50,000 events recorded and analyzed with FlowJo software (FlowJo LLC). The gating strategy is outlined in Supplementary Fig. [10](#MOESM1){ref-type="media"}.

Mass spectrometry-based proteome analysis {#Sec19}
-----------------------------------------

10^9^ *C. crescentus* cells grown in PYE to exponential phase were collected, washed twice with phosphate buffer, resuspended in 50 µl lysis buffer (1% sodium deoxycholate, 0.1 M ammoniumbicarbonate), reduced with 5 mM TCEP for 15 min at 95 °C and alkylated with 10 mM chloroacetamide for 30 min at 37 °C. Samples were digested with trypsin (Promega) at 37 °C overnight (protein to trypsin ratio: 50:1) and desalted on C18 reversed phase spin columns according to the manufacturer's instructions (Microspin, Harvard Apparatus).

One microgram of peptides of each sample were subjected to LC-MS analysis using a dual pressure LTQ-Orbitrap Elite mass spectrometer connected to an electrospray ion source (both Thermo Fisher Scientific). Peptide separation was carried out using an EASY nLC-1000 system (Thermo Fisher Scientific) equipped with a RP-HPLC column (75 μm × 30 cm) packed in-house with C18 resin (ReproSil-Pur C18--AQ, 1.9 μm resin; Dr Maisch GmbH, Ammerbuch-Entringen, Germany) using a linear gradient from 95% solvent A (0.15% formic acid, 2% acetonitrile) and 5% solvent B (98% acetonitrile, 0.15% formic acid) to 28% solvent B over 75 min at a flow rate of 0.2 μl/min. The data acquisition mode was set to obtain one high resolution MS scan in the FT part of the mass spectrometer at a resolution of 240,000 full width at half-maximum (at *m*/*z* 400) followed by MS/MS scans in the linear ion trap of the 20 most intense ions. The charged state screening modus was enabled to exclude unassigned and singly charged ions and the dynamic exclusion duration was set to 20 s. The ion accumulation time was set to 300 ms (MS) and 50 ms (MS/MS). The collision energy was set to 35%, and one microscan was acquired for each spectrum. For all LC-MS measurements, singly charged ions and ions with unassigned charge state were excluded from triggering MS2 events.

To determine changes in protein expressions across samples, a MS1-based label-free quantification was carried out. Therefore, the generated raw files were imported into the Progenesis QI software (Nonlinear Dynamics, Version 2.0) and analyzed using the default parameter settings. MS/MS-data were exported directly from Progenesis QI in mgf format and searched against a decoy database of the forward and reverse sequences of the predicted proteome from *Caulobacter crescentus* (strain NA1000/CB15N) (Uniprot, download date: 08/09/2015, total of (8234 entries) using MASCOT. The search criteria were set as following: full tryptic specificity was required (cleavage after lysine or arginine residues); three missed cleavages were allowed; carbamidomethylation (C) was set as fixed modification; oxidation (M) as variable modification. The mass tolerance was set to 10 ppm for precursor ions and to 0.6 Da for fragment ions. Results from the database search were imported into Progenesis QI and the final peptide measurement list containing the peak areas of all identified peptides, respectively, was exported. This list was further processed and statically analyzed using our in-house developed SafeQuant R script (SafeQuant, <https://github.com/eahrne/SafeQuant> ^[@CR34]^). The peptide and protein false discovery rate was set to 1% using the number of reverse hits in the dataset. All quantitative analyses were performed in biological triplicates. All raw data and results associated with the manuscript have been deposited to the ProteomeXchange Consortium via the PRIDE^[@CR35]^ partner repository with the dataset identifier PXD012739.

Genetic selection for c-di-GMP-independent mutations in *shkA* {#Sec20}
--------------------------------------------------------------

Six independent colonies of strain AKS1 (CB15 rcdG^0^ Δ*lacA*::Ω *ampG*::pNPTStet-ampG) harboring in addition plasmid pAK503-spmX were inoculated into 5 ml PYE containing chloramphenicol (1 mg l^−1^) and oxytetracycline (10 mg l^−1^) and grown overnight. For UV mutagenesis, 2 ml of each culture was distributed in six-well plates and irradiated with 10,000 mJ UV light using a Stratalinker, after which 5 ml PYE containing chloramphenicol (1 mg l^−1^) and oxytetracycline (10 mg l^−1^) were added and cultures grown for 7 h at 30 °C with shaking. Five hundred microliters of each culture were plated on PYE plates containing chloramphenicol (1 mg l^−1^), oxytetracycline (10 mg l^−1^), and kanamycin (6.25 mg l^−1^) and plates incubated at 30 °C for 4 days. All colonies from one plate were pooled, diluted to an OD~660~ of 0.1 and grown for 7 h at 30 °C, and phage lysates were prepared for each independent pool. Following transduction of strain AKS17 (CB15 rcdG^0^ Δ*lacA*::Ω /pAK502-spmX) with individual pool lysates, cells were plated on PYE containing chloramphenicol (1 mg/l), oxytetracycline (10 mg l^−1^), and X-Gal (40 mg l^−1^) and incubated at 30 °C for 3 days. Blue colonies were once restreaked to confirm their blue colony phenotype, followed by colony-PCR using primers 9765 and 9766 and sequencing (Microsynth, Balgach, Switzerland) of the PCR product using primers 9765, 9766, 6011, and 6498.

Genetic screen for mutations abolishing *spmX'-'lacZ* activity {#Sec21}
--------------------------------------------------------------

Transposon mutagenesis was performed by delivery of pSAM-Ec in strain UJ6168 carrying pAK502-spmX by conjugation and cells were plated on PYE containing chloramphenicol (1 mg l^−1^), kanamycin (50 mg l^−1^), nalidixic acid (20 mg l^−1^), and X-Gal (40 mg l^−1^) and incubated at 30 °C for 3 days. White colonies were pooled in 5 ml PYE supplemented with appropriate antibiotics and grown overnight to prepare φCR30 lysates. From this pool lysate transposon insertions were transduced in a clean background (UJ6168/pAK502-spmX), followed by blue/white screening as described above. Lysates were prepared from single white colonies and mutations transduced in a NA1000 wild-type background. Transposon insertion sites were mapped using a two-step semi-arbitrary PCR approach^[@CR36]^. Primers 9058, 9003 and 9004 were used in the first PCR and primers 9058 and 9005 in the second PCR. PCR products were sequenced (Microsynth, Balgach, Switzerland) with primer 9058. In one strain (AKS50), the transposon mapped within *pleD* at position 2′695′825 of the NA1000 reference genome^[@CR37]^.

Protein expression and purification {#Sec22}
-----------------------------------

For isothermal titration calorimetry (ITC) and in vitro phosphorylation experiments shown in Fig. [2](#Fig2){ref-type="fig"}, proteins were expressed and purified as follows. *E. coli* Rosetta 2(DE3) cells were used to express proteins from pET28a and pET32b expression plasmids. Cells were grown in LB-Miller supplemented with the appropriate antibiotics to an OD~600~ of 0.4--0.6, expression was then induced with 0.5 mM IPTG for 4 h at 30 °C. Proteins were purified on an ÄKTApurifier 10 system (GE Healthcare) using 1 ml HisTrap HP columns (GE Healthcare) followed by size exclusion chromatography (HiLoad 16/60 Superdex 200) using the following buffers: lysis buffer (wash buffer supplemented with protease inhibitor, DNase I \[NEB\]), wash buffer (20 mM HEPES-KOH pH 8.0, 0.5 M NaCl, 10% glycerol, 20 mM imidazole, 1 mM DTT), elution buffer (20 mM HEPES-KOH pH 8.0, 0.5 M NaCl, 10% glycerol, 500 mM imidazole, 1 mM DTT), storage buffer (10 mM HEPES-KOH pH 8.0, 50 mM KCl, 10% glycerol, 0.1 mM EDTA, 1 mM DTT). MgCl~2~ was added to reaction mixtures immediately prior to experiments to a final concentration of 5 mM. For all other experiments using purified ShkA, mutant variants thereof and ShkA~REC1~, except NMR experiments (see below), proteins were expressed in *E. coli* BL21(DE3) grown in LB-Miller at 37 °C in 500-ml cultures, with IPTG induction (1 mM) at an OD~600~ of 0.5--0.8 followed by incubation for 4 h. Cells were harvested by centrifugation (5000 *×* *g*, 20 min, 4 °C), washed once with 20 ml of 1X PBS, flash-frozen in liquid N~2~, and stored at −80 °C until purification. For purification, the pellet was resuspended in 8 ml of buffer A (2X PBS containing 500 mM NaCl, 10 mM imidazole and 2 mM β-mercaptoethanol) supplemented with DNaseI (AppliChem) and Complete Protease inhibitor (Roche). After one passage through a French press cell, the suspension was ultra-centrifuged (100,000 *×* *g*, 30 min, 4 °C) and the supernatant was mixed with 800 µl of Ni-NTA slurry, prewashed with buffer A, and incubated for 1--2 h on a rotary wheel at 4 °C. Ni-NTA agarose was loaded on a polypropylene column and washed with at least 50 ml of buffer A, after which the protein was eluted with 2.5 ml of buffer A containing 500 mM imidazole. The eluate was immediately loaded on a PD-10 column pre-equilibrated with kinase buffer (10 mM HEPES-KOH pH 8.0, 50 mM KCl, 10% glycerol, 0.1 mM EDTA, 5 mM MgCl~2~, 5 mM β-mercaptoethanol). The protein was then eluted with 3.5 ml of kinase buffer and stored at 4 °C until further use, usually no longer than one week. Uniformly \[^13^C, ^15^N\]-labeled protein for NMR studies was prepared by growing BL21(DE3) cells harboring pET28a-shkAREC1 in 1 l M9 minimal medium, with 1 g ^15^NH4Cl and 2 g \[*U*-^13^C\] glucose per liter medium, at 37 °C. Expression was induced at an OD~600~ of 0.8 with 1 mM IPTG and cells were harvested 4 h post induction. ShkA~REC1~ was purified using Ni-NTA slurry as described above, followed by size exclusion chromatography (HiLoad 16/60 Superdex 200) on a ÄKTApurifier 10 system (GE Healthcare) with NMR buffer (25 mM Tris pH 7.2 with 50 mM KCl, 2 mM MgSO~4~) and concentration of the sample using Vivaspin6 5 kDa MWCO concentrators (Sartorius).

Isothermal titration calorimetry (ITC) {#Sec23}
--------------------------------------

ITC binding assays were performed with a VP-ITC isothermal titration calorimeter (MicroCal). Concentrations were 12 µM ShkA in the cell and 130 µM cdG in the syringe. ITC Buffer: 10 mM HEPES-KOH pH 8.0, 100 mM NaCl, 10% glycerol, 1 mM DTT. After a first injection of 3 µl, 10 µl was injected at 29 time points. Data analysis was performed with MicroCal (ORIGIN) and fitted with the One binding site model of ORIGIN.

In vitro phosphorylation assays {#Sec24}
-------------------------------

Kinase assays were adapted from^[@CR9]^. Reactions were performed in kinase buffer supplemented with 433 µM ATP and 5-20 µCi \[γ^32^P\]-ATP (3000 Ci/mmol, Hartmann Analytic) at room temperature if not otherwise mentioned. Additional nucleotides were added as indicated in the figures or figure legends. Kinase reactions contained 5 µM ShkA and were run for 3.5 min at room temperature if not otherwise mentioned and stopped by addition of 5X SDS sample buffer and stored on ice, then run on 12.5% SDS-PAGE or precast Mini-Protean TGX (Biorad) gels. Wet gels were exposed to a phosphor screen for 0.5--3 h and then scanned using a Typhoon FLA 7000 imaging system (GE Healthcare), after which gels were stained with Coomassie Brilliant Blue.

C-di-GMP UV-crosslinking assays {#Sec25}
-------------------------------

^32^P-labeled c-di-GMP was prepared by incubation of 250 µCi \[α^32^P\]-GTP (3000 Ci mmol^−1^, Hartmann Analytic) in 200 µl DgcZ reaction buffer (50 mM Tris-HCl pH 7.5, 50 mM NaCl, 5 mM MgCl~2~) with 2 µM purified DgcZ for 24 h at 30 °C. DgcZ (YdeH) was purified as described previously^[@CR38]^. The reaction was stopped by boiling and, after centrifugation (1 min, 16,000 *×* *g*), the supernatant containing radiolabeled c-di-GMP was removed and stored at −20 °C. Non-radio-labeled c-di-GMP was prepared as described previously^[@CR38]^ with the following modifications. 5% (v/v) methanol and 5 mM tetraethylammonium bromide were added to the c-di-GMP reaction and the mixture was loaded on a Luna 10 µM C18(2) 100 Å, 100 × 21.2 mm column (Phenomenex). GTP was removed by isocratic elution in TEAB buffer (5 mM tetraethylammonium bromide, 5% \[v/v\] methanol) over three column volumes (CV), after which c-di-GMP was eluted with a linear gradient from 0--20% ethanol in TEAB buffer over four CV. c-di-GMP was lyophilized overnight, resuspended in ddH~2~O at a concentration of 10 mM and aliquoted. Aliquots were lyophilized and stored at −20 °C. ddH~2~O was added to aliquots to give a 10 mM working stock, the concentration of which was verified by measuring absorbance at 253 nm. A 80 mM stock solutions of hot c-di-GMP was prepared by mixing 10--20 µCi ^32^P-labeled c-di-GMP with 4 µl 1 mM cold c-di-GMP in a final volume of 50 µl. More dilute stock solutions were prepared by mixing with ddH~2~O. UV-crosslinking reactions (16 µl) contained 4 µl of hot c-di-GMP to give the indicated final concentrations and 0.5 µM ShkA, ShkA mutant variants or ShkA~REC1~ in kinase buffer, and were incubated at room temperature for 45 min before UV crosslinking at 4 °C, 254 nm, 2 min on a Caprotec Protein Detector. For competition experiments, reactions contained a 50-fold molar excess of cold c-di-GMP over hot c-di-GMP added from a 10 mM stock. Samples were mixed with 5X SDS sample buffer, boiled for 10 min and run on 12.5% SDS-PAGE or precast Mini-Protean TGX (Biorad) gels. Gels were stained with Coomassie Brilliant Blue, dried and exposed to a phosphor screen that was scanned using a Typhoon FLA 7000 imaging system (GE Healthcare). Bands of autoradiographs were quantified using Fiji and normalized to wild-type ShkA, which was run in parallel to mutant variants or ShkA~REC1~ on the same gel for each experiment. Experiments were repeated twice and values represent means and standard deviations. Binding curves were fitted to a "Binding---saturation, One site---Total" model using Prism 7 (GraphPad).

Nuclear magnetic resonance (NMR) spectroscopy {#Sec26}
---------------------------------------------

All NMR spectra were recorded at 25 °C on a Bruker Avance-700 spectrometer equipped with a cryogenically cooled triple-resonance probe. ShkA~REC1~ protein samples were prepared in 25 mM Tris pH 7.2 with 50 mM KCl and 2 mM MgSO~4~ in 95%/5% H~2~O/D~2~O. For the sequence-specific backbone resonance assignment of 950 μM \[*U*-^15^N, ^13^C\]-ShkA~REC1~, the following NMR experiments were recorded: 2D \[^15^N,^1^H\]-TROSY, 3D HNCA and 3D HNCACB. For the c-di-GMP binding experiments a series of 2D \[^15^N,^1^H\]-TROSY spectra of 200 μM \[*U*-^15^N\]-ShkA~REC1~ were recorded with c-di-GMP concentrations of 0 μM, 20 μM, 50 μM, 100 μM, 150 μM, 200 μM and 400 μM. CSPs (Δδ(HN)) of amide moieties were calculated as $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${{\Delta} \updelta }\left({\mathrm{HN}}\right) = \sqrt {0.5 \cdot \left({{\Delta} {\updelta }}\left(\, {\!}^{1}{\mathrm{H}} \right)^{2} + \left( {0.2 \cdot {{\Delta} {\updelta }}\left({{\ }^{15}{\mathrm{N}}}\right)}\right)^{2}\right)}$$\end{document}$, where $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${{\Delta \updelta }}\left( {{\, }^1{\mathrm{H}}} \right)$$\end{document}$ and $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${{\Delta \updelta }}\left( {{\ }^{15}{\mathrm{N}}} \right)$$\end{document}$, are the amide proton and amide nitrogen chemical shift differences to the reference spectrum, respectively. Combined secondary chemical shifts of Cα and Cβ were calculated relative to the random-coil values of Kjaergaard and Poulson^[@CR39]^.

C-di-GMP extraction and quantifications {#Sec27}
---------------------------------------

Strains AKS371 and AKS412 were grown in 2 ml PYE overnight, diluted 40-fold the next day in 20 ml PYE and grown for 6 h until reaching an OD~660~ of \~0.35. 14 ml were spun down (11,000 *×* *g*, 5 min, 4 °C), the pellet was washed once in 1 ml ddH~2~O (16,000 *×* *g*, 2 min, 4 °C) and snap-frozen in liquid nitrogen. Metabolites were extracted by resuspending the pellet in 300 μl ice-cold extraction solvent (40% \[v/v\] acetonitrile, 40% \[v/v\] methanol, 20% \[v/v\] ddH~2~O) and incubation at 95 °C for 10 min. Extractions were repeated on the pellet twice with 200 μl extraction solvent and the pooled extracts (700 μl) were stored overnight at −80 °C. Remaining debris was removed by centrifugation (16,000 *×* *g*, 10 min, 4 °C), the supernatant was transferred to a fresh microcentrifuge tube and solvent was removed using a Speedvac. LC-MS-based c-di-GMP quantification was performed by the Zentrale Forschungseinrichtung (ZFA) Metabolomics, Medizinische Hochschule Hannover, Germany, and cellular concentrations were calculated as described before^[@CR11]^. Experiments were performed in biological triplicates and values given are means and standard deviations.

Sequence alignments, structure prediction, and modeling {#Sec28}
-------------------------------------------------------

The *C. crescentus* ShkA sequence was blasted against the nonredundant protein sequences (nr) database using default settings and the first 500 hits were aligned in Geneious using the Geneious Alignment algorithm with default settings (Supplementary Data [1](#MOESM3){ref-type="media"}). The alignment was manually checked for the presence of the DDR motif in the REC1-REC2 linker and the sequences that harbored this motif (see Fig. [S3](#MOESM1){ref-type="media"}A) were realigned as described above. This alignment was used to create sequence logos using WebLogo3^[@CR40]^, construct a phylogenetic tree using Geneious Tree Builder with default settings and calculate conservation scores using the ConSurf server^[@CR41]^. Four proteins of the original blast set that do not contain the DDR motif were included in the phylogenetic tree for comparison. Secondary structure prediction for *E. coli* BarA~PRD~ (residues 532--655) was performed with HHPred^[@CR42]^ and the ShkA~REC1~-BarA~PDR~ alignment was generated in Geneious as described above. The ShkA~REC1~-3GRC alignment was generated using HHPred. The ShkA~REC1~ structure was modeled using the SWISS-MODEL workspace^[@CR43]^ with PDB entry 3GRC as the template. CSPs and conservation scores mapped onto the ShkA~REC1~ model were visualized using MacPyMol (PyMOL v1.7.6.6, Schrödinger LLC).
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